Q1 Earnings Forecast for ARTV Issued By Wedbush

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Investment analysts at Wedbush issued their Q1 2025 EPS estimates for Artiva Biotherapeutics in a research note issued to investors on Monday, March 24th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.62) for the quarter. Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.54) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.95) EPS.

A number of other research firms have also weighed in on ARTV. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald lowered their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Trading Down 2.7 %

Artiva Biotherapeutics stock opened at $3.54 on Thursday. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31. The company’s 50 day moving average is $4.78 and its two-hundred day moving average is $9.29.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the business. RA Capital Management L.P. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $152,234,000. Franklin Resources Inc. purchased a new stake in Artiva Biotherapeutics during the third quarter worth approximately $7,435,000. Geode Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the third quarter worth approximately $4,774,000. Samsara BioCapital LLC acquired a new position in Artiva Biotherapeutics in the third quarter valued at approximately $4,506,000. Finally, Wellington Management Group LLP purchased a new position in Artiva Biotherapeutics in the third quarter valued at approximately $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.